0000950170-24-070668.txt : 20240607
0000950170-24-070668.hdr.sgml : 20240607
20240607161756
ACCESSION NUMBER: 0000950170-24-070668
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240606
FILED AS OF DATE: 20240607
DATE AS OF CHANGE: 20240607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kanter Stacy J.
CENTRAL INDEX KEY: 0001775404
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38898
FILM NUMBER: 241029699
MAIL ADDRESS:
STREET 1: C/O APPLIED THERAPEUTICS, INC.
STREET 2: 340 MADISON AVENUE, 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10173
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Applied Therapeutics, Inc.
CENTRAL INDEX KEY: 0001697532
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-220-9226
MAIL ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER COMPANY:
FORMER CONFORMED NAME: Applied Therapeutics Inc.
DATE OF NAME CHANGE: 20170208
4
1
ownership.xml
4
X0508
4
2024-06-06
0001697532
Applied Therapeutics, Inc.
APLT
0001775404
Kanter Stacy J.
C/O APPLIED THERAPEUTICS, INC.
545 FIFTH AVENUE, SUITE 1400
NEW YORK
NY
10017
true
false
false
false
false
Common Stock
2024-06-06
4
A
false
45000
0.00
A
108000
D
Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date.
/s/ Shoshana Shendelman, as attorney-in-fact
2024-06-07